TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Olmesartan Comparison to Losartan in Hypertensive Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged \> 18 years who are not institutionalized and have signed informed consent.~* Mean cuff seated diastolic blood pressure (BP) must be \> 95 mmHg and \< 115 mmHg and a mean cuff seated systolic BP must be \< 180 mmHg when measured at two consecutive qualification study visits during the placebo run-in phase.~* The difference in mean cuff seated diastolic BP must be \< 7 mmHg between two consecutive qualification study visits during the placebo run-in phase.~Exclusion Criteria:~* Subjects with type 2 diabetes mellitus with an HbA1c ≥ 9.5% at Screening.~* Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium, including cardiovascular, renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), endocrine/metabolic (with the exception of non-insulin, dependent type 2 diabetes mellitus with HbA1c \< 9.5% at Screening), hematologic/oncologic (including an active malignancy other than basal cell carcinoma), neurologic and psychiatric diseases.~* Subjects with a history of myocardial infarction, angina, coronary angioplasty, bypass surgery or heart failure within the last 12 months.~* Subjects with any history of New York Heart Association Class III or IV congestive heart failure (CHF). A history of New York Heart Association Class I or II CHF may be exclusionary at the discretion of the Investigator.~* Subjects with a history of cerebrovascular accident or transient ischemic attack within the last 1 year.~* Subjects with clinically significant cardiac conduction defects, including second or third degree atrioventricular (AV) block, left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olmesartan (Type: EXPERIMENTAL): Olmesartan 20 mg once daily for four weeks followed by 40mg one daily for four weeks.
- Placebo followed by Olmesartan (Type: PLACEBO_COMPARATOR): Placebo capsule of olmesartan once daily for 2 weeks, followed by olmesartan 20 mg once daily for two weeks, followed by olmesartan 40 mg for 4 weeks
- Losartan (Type: ACTIVE_COMPARATOR): Losartan 50 mg once daily for four weeks, followed by losartan 100 mg once daily for four weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 65 years old~* Infection with COVID-19 diagnosed with RT-PCR SARS-CoV-2 or withCT-scan of the chest suggesting viral pneumonia of peripheral predominance in a clinically relevant context~* Patient seen in hospitalization or consultation or in nursing home~* Diagnosed within the preceding 3 days~* Having at least one of the following two risk factors for complications:~  * age ≥75 years~ * Peripheral capillary oxygen saturation (SpO2) ≤ 94% ambient air, or a partial oxygen pressure (PaO2) to fraction of inspired oxygen (FiO2) ratio ≤ 300 mmHg~* Patients affiliated with or benefitting from a social security scheme~* Written and signed consent of the patient or a relative or legal representative or, if not possible, emergency inclusion procedure~Exclusion Criteria:~* Organ failure requiring admission to a resuscitation or high dependency unit~* Comorbidity that is life-threatening in the short-term (life expectancy \<3 months)~* Any reason that makes follow-up at day 28 impossible~* Vitamin D supplementation in the previous month, with the exception of treatment providing less than 800 IU of vitamin D per day~* Contraindication for vitamin D supplementation: active granulomatosis (sarcoidosis, tuberculosis, lymphoma), history of calcic lithiasis, known hypervitaminosis D or hypercalcemia, known intolerance to vitamin D~* Participation in another simultaneous trial~* Safeguard of justice~* Peripheral capillary oxygen saturation (SpO2) ≤92% in spite of an oxygen therapy \> 5L/min

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): High dose of vitamin D3
- Comparator group (Type: ACTIVE_COMPARATOR): Standard dose of vitamin D3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertension patient who satisfied below condition at Visit 1.~  * patient who takes antihypertensive drug~    * 140mmHg \<= sitSBP \<= 200mmHg~ * patient who doesn't take antihypertensive drug~    * 160mmHg \<= sitSBP \<= 200mmHg~   * 140mmHg \<= sitSBP \<= 200mmHg at Visit 2~Exclusion Criteria:~* Patient who have received 4 or more antihypertensive drug~* Patient with 20mmHg of difference in sitSBP or 10mmHg of difference in sitDBP between 3 times of BP measuring at Visit 1~* Patient with sitDBP \>= 120mmHg at Visit 2~* Patient with secondary hypertension

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): HCP1401
- Reference (Type: ACTIVE_COMPARATOR): HCP0605

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients at least 18 years of age~Exclusion Criteria:~* Have previously completed or withdrawn from this study or any other study investigating duloxetine or have previously been treated with duloxetine~* Patient diagnosed with major depressive disorder within the past 6 months~* Patient diagnosed with panic disorder, post-traumatic stress disorder, or an eating disorder within the past year~* History of alcohol or any psychoactive substance abuse or dependence within the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Liver biopsy consistent with NASH cirrhosis.~2. Compensated cirrhosis due to NASH.~Key Exclusion Criteria:~1. Other causes of liver disease including but not limited to alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders, primary biliary cirrhosis, drug-induced hepatotoxicity, Wilson's disease, hemochromatosis, and alpha-1-anti-trypsin definition based on medical history and/or centralized read of liver histology.~2. Evidence of drug induced steatohepatitis secondary to amiodarone, corticosteroids, estrogens, methotrexate, tetracycline, or other medications known to cause hepatic steatosis.~3. History of hepatic decompensation including variceal bleeding, ascites, or hepatic encephalopathy.~4. Model of end stage liver disease (MELD) score \>12.~Other protocol-defined inclusion/exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Daily 0.3 mg dose (Type: EXPERIMENTAL): Administered by subcutaneous injection
- Daily 1 mg dose (Type: EXPERIMENTAL): Administered by subcutaneous injection
- Daily 3 mg dose (Type: EXPERIMENTAL): Administered by subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Administered by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interaction of Apelin and Angiotensin in the Human Forearm Circulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old~Exclusion Criteria:~* Lack of informed consent~* Age \< 18 years,~* Current involvement in other research studies,~* Systolic blood pressure \>190 mmHg or \<100 mmHg~* Malignant arrhythmias~* Renal or hepatic failure~* Haemodynamically significant aortic stenosis~* Severe or significant co morbidity~* Women of childbearing potential.~* Any regular medication~* Previous history of any cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Angiotensin II infusion (Type: EXPERIMENTAL): Using forearm venous occlusion plethysmography angiotensin II will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
- Noradrenaline (Type: ACTIVE_COMPARATOR): Using forearm venous occlusion plethysmography noradrenaline will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven adenocarcinoma of the rectum, the lower pole less than 15 cm from the anal verge~* Patient should not have receive any treatment for cancer~* Synchronous metastases with unresectable hepatic and/or lung localization or uncertain resectability (potentially resectable)~* Measurable lesions by RECIST 1.1 (metastasis and primary cancer of the rectum)~* Age ≥ 18 years~* WHO ≤ 2~* ANC ≥ 1.5 x 10 9/L, platelets ≥ 100 x 10 9/L, creatinine clearance ≥ 60 mL/min~* Hemoglobin ≥ 10 g /dL~* Signed informed consent~Exclusion Criteria:~* Rectal Cancer in occlusion requiring surgery or a prosthesis in emergency~* Rectal bleeding severe and active~* Prior pelvic irradiation~* History of cancer, except non-melanoma skin cancer, carcinoma in situ of the cervix treated curatively and other cancers treated curatively if they do not relapse over 3 years,~* Hepatic impairment (total bilirubin\> 1.5 x upper limit of normal (ULN) and serum albumin \<25g / L); known Gilbert's disease~* Uncontrolled severe infection,~* Severe pain (VAS\> 5/10) uncontrollable by opioid therapy~* Symptomatic sensorimotor peripheral neuropathy~* Pregnant or lactating patients or patient of both sexes with childbearing potential and not using adequate contraception method~* Patient receiving or having received an experimental therapy within 4 weeks prior to enter into the study or participating in another clinical study of other experimental drugs~* Known hypersensitivity to any component of the treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single arm study/ non randomized trial (Type: OTHER): FOLFORINOX

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females, between 18 and 55 years of age, inclusive~* Females must be nonpregnant, nonlactating, and either postmenopausal or surgically sterile or practicing an effective method of birth control~* Males must be surgically sterile, abstinent, or practicing an effective method of birth control~* BMI between 20 and 34.9 kg/m2, inclusive~Exclusion Criteria:~* Allergy to lidocaine, midazolam, or other anesthetics/sedatives of similar classes~* Physician-diagnosed migraine headaches within 3 years~* Previous enrollment in a TR-701 or TR-701 FA trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- healthy volunteer (Type: EXPERIMENTAL): healthy volunteers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Acupuncture for Total Knee or Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female (age 52 to 85) or male (age 18-85) patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty at the Bone-and Joint Institute at Hartford Hospital~* Patients classified as high-anxiety based on having a score of \>10 on the Amsterdam Preoperative Anxiety and Information Scale (APAIS-A-T). The APAIS-A-T is a modified survey that reliably quantifies total preoperative anxiety using summed scores for anesthesia and surgery-related anxiety; a minimum score of 11 is the most accurate cutoff to identify patients with anxiety~Exclusion Criteria:~* Unable to give consent~* Uncontrolled diabetes (HbA1c ≥ 8.0%)~* Infection at any of the acupuncture points~* Known allergy to metals~* Abnormal laboratory blood work values (INR\>1.5, if available; platelet count \<70,000, if available)~* Patients with active ongoing coagulopathy based on lab data (INR \>1.5) and/or on current anticoagulant use which increases bleeding risk.~* Non-English speaking~* Revision TKA or THA~* Women of reproductive age or under the age of 52 years old, as acupuncture is not recommended during pregnancy. They were excluded due to the potential conflict between our institute's standard timing for pregnancy tests on the day of surgery and the scheduled preoperative acupuncture session for the study, to avoid unwanted delays in the operating room schedule.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Acupuncture (Type: EXPERIMENTAL): Preoperative acupuncture
- Control (Type: NO_INTERVENTION): No acupuncture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female 18 to 45 years of age at the time of consent~2. BMI of 19-26Kg/m2 and weight of 50-100kg~3. Must provide written informed consent, and in the investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements~Exclusion Criteria:~1. Subjects who have a medical history of liver, kidney, cardiovascular, nervous / mental, gastrointestinal, respiratory, urinary, endocrine~2. Subjects who have a history of relapse or chronic infection, or a history of acute infection within 2 weeks;~3. Subjects who have previously used anti-IL-12 / 23 or anti-il-23 drugs;~4. Subjects who have clinically significant abnormalities determined by vital signs, physical examination, and laboratory measurements;~5. Subjects who are not suitable for this trial due to other reasons In the investigator' opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): IBI112 SC dose1
- Cohort 2 (Type: EXPERIMENTAL): IBI112 SC dose2
- Cohort 3 (Type: EXPERIMENTAL): IBI112 SC dose3
- Cohort 4 (Type: EXPERIMENTAL): IBI112 IV dose4
- Cohort 5 (Type: EXPERIMENTAL): IBI112 IV dose3
- Cohort 6 (Type: EXPERIMENTAL): IBI112 SC dose5
- Cohort 7 (Type: EXPERIMENTAL): IBI112 IV dose5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of adult-onset Rheumatoid Arthritis (RA) for a duration of at least 6 months but not longer than 5 years~* positive Rheumatoid Factor (RF) and/or positive anti Cyclic Citrullinated Peptide (anti-CCP)~* active RA disease~* subjects must have failed at least one traditional Disease Modifying Anti-Rheumatic Drug (DMARD).~* subject is naïve to RA related biologics~Exclusion Criteria:~* a diagnosis of any other inflammatory arthritis~* history of infected joint prosthesis, or other significant infection~* known Tuberculosis (TB) disease or high risk of acquiring TB infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18\~65 years.~* Pregnancy tests of female patients must be negative. All patients with effective birth control measures during treatment period and 6 months after the cessation of treatment.~* Chronic HCV infection evidence: HCV RNA or anti-HCV positive \>6 months; liver biopsy evidence; vital signs, symptoms, exposure history, and results of laboratory test and iconography examination support diagnosis of chronic hepatitis C.~* HCV RNA≥2000IU/ml.~Exclusion Criteria:~* Pregnant or lactating women.~* Mental disorder or physical disability.~* WBC\<3000/mm3, or ANC \<1500/mm3, or PLT \<90,000/mm3.~* Received interferon treatment within the previous 6 months or shew no response to interferon.~* Co-infection with HIV, HAV, HBV, HEV.~* Evidence of hepatic decompensation.~* Chest X-ray with clinically significant active inflammatory process, history of significant pulmonary disease or any history of interstitial lung disease.~* History of hypothyroidism or current treatment for thyroid disease.~* Diabetes mellitus.~* Uncontrolled significant chronic medical conditions other than chronic hepatitis C or other conditions which in the opinion of the investigator preclude enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Ypeginterferon alfa-2b 90mcg per Week, with Ribavirin 1000-1200mg/d
- Group 2 (Type: EXPERIMENTAL): Ypeginterferon alfa-2b 135mcg per Week, with Ribavirin 1000-1200mg/d
- Group 3 (Type: EXPERIMENTAL): Ypeginterferon alfa-2b 180mcg per Week, with Ribavirin 1000-1200mg/d
- Group 4 (Type: ACTIVE_COMPARATOR): Pegasys 180mcg per Week, with Ribavirin 1000-1200mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete